$HRMY
Harmony Biosciences Holdings Inc

2022 Q3 Form 10-Q Financial Statement

#000155837022011556 Filed on August 02, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $117.2M $107.0M $85.31M
YoY Change 45.18% 44.98% 42.97%
Cost Of Revenue $22.96M $18.92M $14.72M
YoY Change 57.21% 49.14% 41.38%
Gross Profit $94.25M $88.11M $70.60M
YoY Change 42.52% 44.12% 43.3%
Gross Profit Margin 80.41% 82.32% 82.75%
Selling, General & Admin $41.80M $42.32M $35.46M
YoY Change 25.38% 35.11% 18.0%
% of Gross Profit 44.35% 48.04% 50.23%
Research & Development $40.55M $12.67M $7.578M
YoY Change 245.41% 94.95% 61.96%
% of Gross Profit 43.02% 14.38% 10.73%
Depreciation & Amortization $6.063M $6.055M $117.0K
YoY Change 29.77% 28.07% 17.0%
% of Gross Profit 6.43% 6.87% 0.17%
Operating Expenses $82.35M $54.99M $43.04M
YoY Change 82.69% 45.39% 23.92%
Operating Profit $11.90M $33.12M $27.56M
YoY Change -43.47% 42.06% 89.61%
Interest Expense -$3.990M -$3.927M -$4.169M
YoY Change -26.51% -45.66% -41.5%
% of Operating Profit -33.53% -11.86% -15.13%
Other Income/Expense, Net $56.00K $42.00K -$2.000K
YoY Change 950.0% -90.0%
Pretax Income $7.967M $29.23M $23.39M
YoY Change -175.72% 81.68% 216.61%
Income Tax -$79.98M $5.700M $1.900M
% Of Pretax Income -1003.84% 19.5% 8.12%
Net Earnings $87.94M $23.53M $21.49M
YoY Change -1014.17% 66.69% 190.89%
Net Earnings / Revenue 75.03% 21.99% 25.18%
Basic Earnings Per Share $1.48 $0.40 $0.36
Diluted Earnings Per Share $1.44 $0.39 $0.35
COMMON SHARES
Basic Shares Outstanding 59.16M 59.06M 58.91M
Diluted Shares Outstanding 61.21M 60.92M 60.59M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $307.8M $254.2M $224.5M
YoY Change 62.23% 59.17% 58.99%
Cash & Equivalents $261.3M $236.5M $224.5M
Short-Term Investments $46.42M $17.64M
Other Short-Term Assets $4.108M $3.674M $3.410M
YoY Change 29.06% 135.66% -60.35%
Inventory $3.900M $4.208M $4.597M
Prepaid Expenses $11.25M $10.83M $9.618M
Receivables $55.07M $49.82M $38.13M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $382.1M $322.7M $280.3M
YoY Change 58.74% 57.64% 57.71%
LONG-TERM ASSETS
Property, Plant & Equipment $680.0K $695.0K $748.0K
YoY Change -27.43% -26.38% -6.5%
Goodwill
YoY Change
Intangibles $166.9M $172.9M $178.8M
YoY Change 12.35% 12.89%
Long-Term Investments $8.280M $4.747M
YoY Change
Other Assets $3.079M $3.264M $3.413M
YoY Change 1925.66% 2047.37% 279.22%
Total Long-Term Assets $261.4M $182.3M $183.7M
YoY Change 73.79% 17.65% 15.13%
TOTAL ASSETS
Total Short-Term Assets $382.1M $322.7M $280.3M
Total Long-Term Assets $261.4M $182.3M $183.7M
Total Assets $643.5M $505.0M $464.0M
YoY Change 64.53% 40.41% 37.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.05M $6.661M $6.904M
YoY Change 140.46% 232.05% 56.91%
Accrued Expenses $85.61M $45.63M $39.38M
YoY Change 150.14% 71.19% 36.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.000M $2.000M $2.000M
YoY Change 0.0%
Total Short-Term Liabilities $107.4M $65.76M $56.53M
YoY Change 125.43% 79.71% 69.25%
LONG-TERM LIABILITIES
Long-Term Debt $189.7M $189.8M $189.9M
YoY Change -0.18% -2.97% -2.57%
Other Long-Term Liabilities $2.498M $2.930M $3.078M
YoY Change 80.75% 212.03% 270.4%
Total Long-Term Liabilities $192.2M $192.7M $193.0M
YoY Change 0.4% -1.94% -1.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $107.4M $65.76M $56.53M
Total Long-Term Liabilities $192.2M $192.7M $193.0M
Total Liabilities $299.6M $258.5M $249.5M
YoY Change 25.31% 10.88% 8.78%
SHAREHOLDERS EQUITY
Retained Earnings -$320.6M -$408.6M -$432.1M
YoY Change -32.68% -12.45%
Common Stock $664.7M $655.1M $646.6M
YoY Change 5.79% 10.43% 64661500.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $343.9M $246.5M $214.5M
YoY Change
Total Liabilities & Shareholders Equity $643.5M $505.0M $464.0M
YoY Change 64.53% 40.41% 37.56%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income $87.94M $23.53M $21.49M
YoY Change -1014.17% 66.69% 190.89%
Depreciation, Depletion And Amortization $6.063M $6.055M $117.0K
YoY Change 29.77% 28.07% 17.0%
Cash From Operating Activities $55.21M $33.73M $28.85M
YoY Change 81.45% 86.67% 130.26%
INVESTING ACTIVITIES
Capital Expenditures -$86.00K -$41.00K $45.00K
YoY Change -7.53% -80.0% 1025.0%
Acquisitions
YoY Change
Other Investing Activities -$32.36M -$22.41M
YoY Change
Cash From Investing Activities -$32.45M -$22.45M -$40.05M
YoY Change 34787.1% 10849.76% -59.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $500.0K
YoY Change
Cash From Financing Activities 2.050M 750.0K 1.383M
YoY Change -754.95% 15.38% 11425.0%
NET CHANGE
Cash From Operating Activities 55.21M 33.73M 28.85M
Cash From Investing Activities -32.45M -22.45M -40.05M
Cash From Financing Activities 2.050M 750.0K 1.383M
Net Change In Cash 24.81M 12.03M -9.810M
YoY Change -17.35% -35.0% -88.78%
FREE CASH FLOW
Cash From Operating Activities $55.21M $33.73M $28.85M
Capital Expenditures -$86.00K -$41.00K $45.00K
Free Cash Flow $55.29M $33.77M $28.81M
YoY Change 81.18% 84.8% 129.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
660000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7208000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
4881000
CY2022Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
449000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
449000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3298000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1581000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1527000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1777000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2233000
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3358000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3760000
us-gaap Operating Lease Payments
OperatingLeasePayments
872000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 215
CY2022Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
us-gaap Operating Lease Payments
OperatingLeasePayments
538000
CY2022Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022Q2 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4884403
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity File Number
EntityFileNumber
001-39450
dei Entity Registrant Name
EntityRegistrantName
HARMONY BIOSCIENCES HOLDINGS, INC.
CY2021Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
97180000
us-gaap Net Income Loss
NetIncomeLoss
21503000
CY2021Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
dei Entity Central Index Key
EntityCentralIndexKey
0001802665
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59117749
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58825769
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2279923
dei Entity Address Address Line1
EntityAddressAddressLine1
630 W.
dei Entity Address Address Line2
EntityAddressAddressLine2
Germantown Pike
dei Entity Address City Or Town
EntityAddressCityOrTown
Plymouth Meeting
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19462
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
539-9800
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 value per share
dei Trading Symbol
TradingSymbol
HRMY
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59161397
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
7213000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
236533000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
234309000
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
17638000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
49822000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34843000
CY2022Q2 us-gaap Inventory Net
InventoryNet
4208000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4432000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10827000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7637000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
3674000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3218000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
322702000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
284439000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
695000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
820000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2022Q2 us-gaap Long Term Investments
LongTermInvestments
4747000
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
172876000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
143919000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3264000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3515000
CY2022Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
182332000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
149004000
CY2022Q2 us-gaap Assets
Assets
505034000
CY2021Q4 us-gaap Assets
Assets
433443000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6661000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1001000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
9165000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45626000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40249000
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4264000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1360000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
65764000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53775000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189807000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189984000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2930000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3177000
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
192737000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
193161000
CY2022Q2 us-gaap Liabilities
Liabilities
258501000
CY2021Q4 us-gaap Liabilities
Liabilities
246936000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-3927000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22163000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59117749
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58825769
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
655143000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
640104000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-408582000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-453598000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
246533000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186507000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
505034000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
433443000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107028000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73821000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
192341000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
133495000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18921000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12687000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33637000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23097000
CY2022Q2 us-gaap Gross Profit
GrossProfit
88107000
CY2021Q2 us-gaap Gross Profit
GrossProfit
61134000
us-gaap Gross Profit
GrossProfit
158704000
us-gaap Gross Profit
GrossProfit
110398000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12668000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6498000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20246000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11177000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20160000
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
17022000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
37743000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
32529000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14302000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40043000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28848000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
54991000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
37822000
us-gaap Operating Expenses
OperatingExpenses
98032000
us-gaap Operating Expenses
OperatingExpenses
72554000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
33116000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
23312000
us-gaap Operating Income Loss
OperatingIncomeLoss
60672000
us-gaap Operating Income Loss
OperatingIncomeLoss
37844000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
42000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
40000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58635195
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186507000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-7227000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8096000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-14354000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
29231000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
16089000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
52616000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
23475000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5700000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1972000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1972000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
23531000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
14117000
us-gaap Net Income Loss
NetIncomeLoss
45016000
us-gaap Net Income Loss
NetIncomeLoss
21503000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-29000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-29000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
23502000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
14117000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
44987000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
21503000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.38
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.37
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59063358
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56940840
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58986370
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56916282
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60922672
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58592876
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60759026
us-gaap Net Income Loss
NetIncomeLoss
45016000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-29000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3133000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11906000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
246533000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
214503000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
23531000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-29000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1250000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7278000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
246533000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
126551000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
107879000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
14117000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
648000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3907000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
126551000
us-gaap Profit Loss
ProfitLoss
45016000
us-gaap Profit Loss
ProfitLoss
21503000
us-gaap Depreciation
Depreciation
211000
us-gaap Depreciation
Depreciation
200000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11043000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9208000
us-gaap Share Based Compensation
ShareBasedCompensation
11906000
us-gaap Share Based Compensation
ShareBasedCompensation
7208000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
361000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
-130000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
823000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1361000
us-gaap Other Noncash Expense
OtherNoncashExpense
770000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
14979000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9019000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-224000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1128000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3707000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
622000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
5660000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-550000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5407000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2606000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-152000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-37000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
62583000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
30600000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
22406000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
86000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
205000
hrmy Cash Paid For Milestones
CashPaidForMilestones
40000000
hrmy Cash Paid For Milestones
CashPaidForMilestones
100000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-62492000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-100205000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3133000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
660000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2133000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
660000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2224000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-68945000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235059000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229381000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
237283000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
160436000
us-gaap Interest Paid Net
InterestPaidNet
7524000
us-gaap Interest Paid Net
InterestPaidNet
13092000
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
410239
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-408582000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-453598000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
236533000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
156782000
CY2019Q3 hrmy License Agreement Milestone Payments Paid
LicenseAgreementMilestonePaymentsPaid
2000000
CY2019Q3 hrmy License Agreement Additional Milestone Payments Due
LicenseAgreementAdditionalMilestonePaymentsDue
102000000
CY2019Q3 hrmy Licensing Agreement Milestone Fees
LicensingAgreementMilestoneFees
2000000
CY2022Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
17125000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
16396000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
191984000
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Uncertainties related to the magnitude and duration of COVID-19, the extent to which it will impact our future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending and health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic have increased the complexity of developing estimates and assumptions used in the preparation of the unaudited condensed consolidated financial statements, including the carrying amounts of long-lived assets, and the intangible asset. Actual results may differ significantly from our estimates as a result of COVID-19.</p>
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
236533000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
234309000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
237283000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235059000
CY2019Q4 hrmy License Agreement Milestone Payments Paid
LicenseAgreementMilestonePaymentsPaid
75000000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Concentrations of Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s cash and money market funds are held in two financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary As of June 30, 2022, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 38% of gross accounts receivable; PANTHERx Specialty Pharmacy LLC (“Pantherx”, which accounted for 34% of gross accounts receivable: and, Accredo Health Group, Inc. (“Accredo”), which accounted for 28% of gross accounts receivable. As of December 31, 2021, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 40% of gross accounts receivable; Pantherx, which accounted for 31% of gross accounts receivable; and CVS Caremark, which accounted for 29% of gross accounts receivable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the six months ended June 30, 2022, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 39% of gross product revenues; Pantherx accounted for 32% of gross product revenues; and Accredo accounted for 29% of gross product revenues. For the six months ended June 30, 2021 three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 37% of gross product revenues; Pantherx accounted for 35% of gross product revenues; and Accredo accounted for 28% of gross product revenues.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company depends on a single source supplier for its product and active pharmaceutical ingredient.</p>
hrmy Concentrations Of Risk Number Of Financial Institutions
ConcentrationsOfRiskNumberOfFinancialInstitutions
2
CY2022Q2 us-gaap Inventory Net
InventoryNet
4208000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4432000
CY2022Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
194568000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
606000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
986000
CY2022Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1809000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1787000
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2242000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2108000
CY2022Q2 us-gaap Inventory Gross
InventoryGross
4657000
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5961000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4629000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11043000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9208000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
11923000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
23845000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
23845000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
23845000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
23845000
CY2022Q2 hrmy Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
65573000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
172876000
CY2022Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
215000000
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
175000000
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
42124000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
31081000
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
172876000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
143919000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189807000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189984000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
465000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2961000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
87330
CY2022Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
17125000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
16396000
CY2022Q2 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
22558000
CY2021Q4 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
17141000
CY2022Q2 us-gaap Interest Payable Current
InterestPayableCurrent
2198000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2125000
CY2022Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1644000
CY2021Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1983000
CY2022Q2 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
253000
CY2021Q4 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
658000
CY2022Q2 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
928000
CY2021Q4 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1645000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
920000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
301000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45626000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40249000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2018Q2 hrmy Operating Lease Office Space
OperatingLeaseOfficeSpace
15000
CY2018Q4 hrmy Operating Lease Office Space
OperatingLeaseOfficeSpace
13000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
392000
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
198500000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
199500000
CY2022Q2 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
6693000
CY2021Q4 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
7516000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
191807000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1000000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2000000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
20000000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
155500000
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
198500000
CY2022Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
3773000
CY2021Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
6582000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
7597000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
13092000
CY2022Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
411000
CY2021Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
697000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
823000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1361000
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
4184000
CY2021Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
7279000
us-gaap Interest Expense Debt
InterestExpenseDebt
8420000
us-gaap Interest Expense Debt
InterestExpenseDebt
14453000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
293000
us-gaap Operating Lease Cost
OperatingLeaseCost
777000
us-gaap Operating Lease Cost
OperatingLeaseCost
557000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M6D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.038
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2985000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
840000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1672000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
951000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
30000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3493000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
135000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3358000
CY2022Q2 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each share
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7257
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7499
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0199
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0333
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0066
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0144
CY2022Q2 hrmy Securities Outstanding Included In Computation Of Utilizing Treasury Stock Method
SecuritiesOutstandingIncludedInComputationOfUtilizingTreasuryStockMethod
1859314
CY2021Q2 hrmy Securities Outstanding Included In Computation Of Utilizing Treasury Stock Method
SecuritiesOutstandingIncludedInComputationOfUtilizingTreasuryStockMethod
1652036
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5716597
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.53
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M2D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1463367
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
48.90
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
278305
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.87
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
28.95
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6814329
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.63
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M13D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
hrmy Securities Outstanding Included In Computation Of Utilizing Treasury Stock Method
SecuritiesOutstandingIncludedInComputationOfUtilizingTreasuryStockMethod
1772656
hrmy Securities Outstanding Included In Computation Of Utilizing Treasury Stock Method
SecuritiesOutstandingIncludedInComputationOfUtilizingTreasuryStockMethod
1718912
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5058223
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4951280
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5144881
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.38
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7371000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3807000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12267000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7058000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
90381000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M18D
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
23531000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
14117000
us-gaap Net Income Loss
NetIncomeLoss
45016000
us-gaap Net Income Loss
NetIncomeLoss
21503000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.76
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.37
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59063358
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56940840
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58986370
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56916282
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60922672
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58592876
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60759026
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58635195
CY2022Q2 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
0
CY2021Q4 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
0

Files In Submission

Name View Source Status
0001558370-22-011556-index-headers.html Edgar Link pending
0001558370-22-011556-index.html Edgar Link pending
0001558370-22-011556.txt Edgar Link pending
0001558370-22-011556-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hrmy-20220630.xsd Edgar Link pending
hrmy-20220630x10q.htm Edgar Link pending
hrmy-20220630x10q_htm.xml Edgar Link completed
hrmy-20220630xex10d1.htm Edgar Link pending
hrmy-20220630xex31d1.htm Edgar Link pending
hrmy-20220630xex31d2.htm Edgar Link pending
hrmy-20220630xex32d1.htm Edgar Link pending
hrmy-20220630xex32d2.htm Edgar Link pending
hrmy-20220630_cal.xml Edgar Link unprocessable
hrmy-20220630_def.xml Edgar Link unprocessable
hrmy-20220630_lab.xml Edgar Link unprocessable
hrmy-20220630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending